Abstract

The drug metabolism field has long recognized the beneficial and sometimes deleterious influence of microbiota in the absorption, distribution, metabolism, and excretion of drugs. Early pioneering work with the sulfanilamide precursor prontosil pointed toward the necessity not only to better understand the metabolic capabilities of the microbiota but also, importantly, to identify the specific microbiota involved in the generation and metabolism of drugs. However, technological limitations important for cataloging the microbiota community as well as for understanding and/or predicting their metabolic capabilities hindered progress. Current advances including mass spectrometry-based metabolite profiling as well as culture-independent sequence-based identification and functional analysis of microbiota have begun to shed light on microbial metabolism. In this review, case studies will be presented to highlight key aspects (e.g., microbiota identification, metabolic function and prediction, metabolite identification, and profiling) that have helped to clarify how the microbiota might impact or be impacted by drug metabolism. Lastly, a perspective of the future of this field is presented that takes into account what important knowledge is lacking and how to tackle these problems.

Original languageEnglish (US)
Pages (from-to)1987-1997
Number of pages11
JournalChemical Research in Toxicology
Volume29
Issue number12
DOIs
StatePublished - Dec 19 2016

Fingerprint

Microbiota
Drug Interactions
Metabolism
Pharmaceutical Preparations
Metabolites
Functional analysis
Cataloging
Mass spectrometry
Mass Spectrometry

All Science Journal Classification (ASJC) codes

  • Toxicology

Cite this

@article{efc7cecc464a4e50ba7dae3cac9f8ced,
title = "Omics Approaches to Probe Microbiota and Drug Metabolism Interactions",
abstract = "The drug metabolism field has long recognized the beneficial and sometimes deleterious influence of microbiota in the absorption, distribution, metabolism, and excretion of drugs. Early pioneering work with the sulfanilamide precursor prontosil pointed toward the necessity not only to better understand the metabolic capabilities of the microbiota but also, importantly, to identify the specific microbiota involved in the generation and metabolism of drugs. However, technological limitations important for cataloging the microbiota community as well as for understanding and/or predicting their metabolic capabilities hindered progress. Current advances including mass spectrometry-based metabolite profiling as well as culture-independent sequence-based identification and functional analysis of microbiota have begun to shed light on microbial metabolism. In this review, case studies will be presented to highlight key aspects (e.g., microbiota identification, metabolic function and prediction, metabolite identification, and profiling) that have helped to clarify how the microbiota might impact or be impacted by drug metabolism. Lastly, a perspective of the future of this field is presented that takes into account what important knowledge is lacking and how to tackle these problems.",
author = "Nichols, {Robert G.} and Hume, {Nicole E.} and Smith, {Philip B.} and Peters, {Jeffrey Maurice} and Patterson, {Andrew David}",
year = "2016",
month = "12",
day = "19",
doi = "10.1021/acs.chemrestox.6b00236",
language = "English (US)",
volume = "29",
pages = "1987--1997",
journal = "Chemical Research in Toxicology",
issn = "0893-228X",
publisher = "American Chemical Society",
number = "12",

}

Omics Approaches to Probe Microbiota and Drug Metabolism Interactions. / Nichols, Robert G.; Hume, Nicole E.; Smith, Philip B.; Peters, Jeffrey Maurice; Patterson, Andrew David.

In: Chemical Research in Toxicology, Vol. 29, No. 12, 19.12.2016, p. 1987-1997.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Omics Approaches to Probe Microbiota and Drug Metabolism Interactions

AU - Nichols, Robert G.

AU - Hume, Nicole E.

AU - Smith, Philip B.

AU - Peters, Jeffrey Maurice

AU - Patterson, Andrew David

PY - 2016/12/19

Y1 - 2016/12/19

N2 - The drug metabolism field has long recognized the beneficial and sometimes deleterious influence of microbiota in the absorption, distribution, metabolism, and excretion of drugs. Early pioneering work with the sulfanilamide precursor prontosil pointed toward the necessity not only to better understand the metabolic capabilities of the microbiota but also, importantly, to identify the specific microbiota involved in the generation and metabolism of drugs. However, technological limitations important for cataloging the microbiota community as well as for understanding and/or predicting their metabolic capabilities hindered progress. Current advances including mass spectrometry-based metabolite profiling as well as culture-independent sequence-based identification and functional analysis of microbiota have begun to shed light on microbial metabolism. In this review, case studies will be presented to highlight key aspects (e.g., microbiota identification, metabolic function and prediction, metabolite identification, and profiling) that have helped to clarify how the microbiota might impact or be impacted by drug metabolism. Lastly, a perspective of the future of this field is presented that takes into account what important knowledge is lacking and how to tackle these problems.

AB - The drug metabolism field has long recognized the beneficial and sometimes deleterious influence of microbiota in the absorption, distribution, metabolism, and excretion of drugs. Early pioneering work with the sulfanilamide precursor prontosil pointed toward the necessity not only to better understand the metabolic capabilities of the microbiota but also, importantly, to identify the specific microbiota involved in the generation and metabolism of drugs. However, technological limitations important for cataloging the microbiota community as well as for understanding and/or predicting their metabolic capabilities hindered progress. Current advances including mass spectrometry-based metabolite profiling as well as culture-independent sequence-based identification and functional analysis of microbiota have begun to shed light on microbial metabolism. In this review, case studies will be presented to highlight key aspects (e.g., microbiota identification, metabolic function and prediction, metabolite identification, and profiling) that have helped to clarify how the microbiota might impact or be impacted by drug metabolism. Lastly, a perspective of the future of this field is presented that takes into account what important knowledge is lacking and how to tackle these problems.

UR - http://www.scopus.com/inward/record.url?scp=85006800498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006800498&partnerID=8YFLogxK

U2 - 10.1021/acs.chemrestox.6b00236

DO - 10.1021/acs.chemrestox.6b00236

M3 - Review article

C2 - 27782392

AN - SCOPUS:85006800498

VL - 29

SP - 1987

EP - 1997

JO - Chemical Research in Toxicology

JF - Chemical Research in Toxicology

SN - 0893-228X

IS - 12

ER -